Survey of Human Rabies Immune Globulin Safety in Children

The Methodist Hospital Research Institute35 enrolled

Overview

This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States. The safety of human rabies immune globulin (HRIG) 300 IU/mL product (HyperRAB®) in pediatric patients has not been fully established. The purpose of this study is to evaluate the safety of HRIG 300 IU/mL when given to pediatric patients per standard of care for rabies postexposure prophylaxis (PEP) in the ED.

BACKGROUND: Rabies PEP consists of thorough wound cleansing, administration of HRIG 20 IU/kg body weight, and 4 to 5 doses of rabies vaccine. The safety of HRIG 300 IU/mL has been confirmed only for adult patients. Although the safety of HRIG 300 IU/mL in the pediatric population has not been fully established, there is no age limit on the FDA approved indication for HRIG 300 IU/mL, and it is routinely administered to pediatric patients as standard of care in the United States. STUDY DESIGN: This observational, multicenter, prospective study will collect information on safety events that occur up to 30 days after standard of care administration of HRIG 300 IU/mL among pediatric patients (age ≤17 years) at up to 5 study sites in the United States. Safety data will be collected using surveys and chart review of the health record. All participants will receive HRIG 300 IU/mL per standard of care prior to joining this study. The day of HRIG 300 IU/mL administration will be defined as day 0. The study will conduct Survey 1 on day 2 and Survey 2 on day 10 to collect information on adverse events (AEs). Investigators will review the electronic health record on day 30 to collect additional information on AEs. If a serious adverse event is detected during Survey 1, Survey 2, or the 30-day chart review and is not previously documented as being resolved or stabilized the study will conduct Survey 3 on day 30.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rabies Rabies Human

Eligibility

Sex: ALLMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria 1. Received HRIG 300 IU/mL for rabies PEP during an ED encounter visit 2. Aged ≤17 years Exclusion Criteria 1. HRIG 300 IU/mL dose given is \<18 IU/kg or \>22 IU/kg 2. Patient is admitted or transferred to a hospital from the ED for further management of injuries related to the animal exposure 3. Patient has a history of rabies vaccine or rabies immune globulin administration 4. Legally authorized representative (parent) does not speak English if patient is \<7 years old 5. Legally authorized representative (parent) or patient does not speak English if patient is 7 to 17 years old 6. Inability to obtain consent 1. More than 3 days passed since HRIG 300 IU/mL administration prior to screen 2. Unable to contact legally authorized representative (parent) and/or patient within 3 days of HRIG 300 IU/mL administration 3. Legally authorized representative (parent) and/or patient declined participation 7. Administration sites for HRIG are unknown

Outcomes

Primary Outcomes

Incidence of local and systemic adverse events (AEs) within 2 days of HRIG 300 IU/mL administration

Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration

Time frame: Within 2 days of HRIG 300 IU/mL administration

Secondary Outcomes

Cumulative incidence of all local and systemic AEs within 10 days of HRIG 300 IU/mL administration

Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration

Time frame: Within 10 days of HRIG 300 IU/mL administration

Cumulative incidence of all local and systemic AEs within 30 days of HRIG 300 IU/mL administration

Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration

Time frame: Within 30 days of HRIG 300 IU/mL administration

Cumulative incidence of all local and systemic serious adverse events (SAEs) within 30 days of HRIG 300 IU/mL administration

Proportion of patients with 1 or more SAE deemed as possibly/definitely related to HRIG 300 IU/mL administration. An AE is considered "serious" if any of the following outcomes occur: * Death * Life-threatening AE (life-threatening in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * In-patient hospitalization or prolongation of existing hospitalization * A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions * An important medical event (refers to events which may not be immediately life-threatening, or result in death, or hospitalization, but from medical and scientific judgment, may jeopardize the participant or/and may require medical or surgical intervention to prevent one of the other outcomes listed above).

Time frame: Within 30 days of HRIG 300 IU/mL administration

Type and severity of individual local and systemic AEs detected within 30 days of HRIG 300 IU/mL administration

Proportions of AEs that are local vs systemic and proportions of AEs that are mild, moderate, or severe among AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration

Time frame: Within 30 days of HRIG 300 IU/mL administration

Survey of Human Rabies Immune Globulin Safety in Children

Overview

Conditions

Interventions

Eligibility

Locations (2)

Outcomes

Primary Outcomes

Secondary Outcomes